glp 1 drugs and cancer Could GLP-1 Reduce Obesity-Related Cancers in the Future? Could GLP-1 drugs reduce cancer

Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes

Laughton Macallum

Clinical trials of GLP-1RAs have primarily focused on patients with obesity or overweight, yet the effectiveness in the cardiovascular protection appears independent of baseline BMI range (265)

Trial data showed that Saxenda , in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone

From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus